3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Lung Neoplasms
3
Colorectal Neoplasms
3
Lymphoma
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Quality of Life
1
Pseudomyxoma Peritonei
1
Prostatic Neoplasms
1
Paranasal Sinus Neoplasms
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Pain
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mouth Neoplasms
1
Mixed Dementias
1
Mesothelioma, Malignant
1
Meningeal Carcinomatosis
1
Maxillary Sinus Neoplasms
1
Lymphoma, Follicular
1
Lewy Body Disease
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Interventions
Paclitaxel
177
Carboplatin
177
Bevacizumab
72
Topotecan
55
liposomal doxorubicin
54
Gemcitabine
53
Cisplatin
46
Docetaxel
39
Cyclophosphamide
37
olaparib
32
Filgrastim
31
pembrolizumab
29
Doxorubicin
26
niraparib
24
Taxes
23
Drug Therapy
23
Peripheral Blood Stem Cell Transplantation
20
Etoposide
17
veliparib
15
Nivolumab
14
sargramostim
13
Surveys and Questionnaires
13
Immunoglobulin G
13
Disulfides
13
pazopanib
12
Ifosfamide
12
Albumin-Bound Paclitaxel
12
durvalumab
11
atezolizumab
11
Trabectedin
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Ovarian Neoplasms
×
Referral and Consultation
×
Clear all
NCT02821793
2025-07-01
PRIORITY
Institut Bergonié
Completed
346 enrolled
9 charts